Want to see SLS full AI Analyst Report?
SLS Stock Chart & Stats
$4.11
-$0.10(-9.43%)
At close: 4:00 PM EST
$4.11
-$0.10(-9.43%)
Day’s Range― - ―
52-Week Range$1.39 - $15.88
Previous CloseN/A
Volume1.43M
Average Volume (3M)9.71M
Market Cap
$2.40B
Enterprise Value$623.27
Total Cash (Recent Filing)$107.20M
Total Debt (Recent Filing)$871.00K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding186,032,580
10 Day Avg. Volume8,241,153
30 Day Avg. Volume9,709,915
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)5.80
Price to Sales (P/S)0.00
P/FCF Ratio-14.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.50Price Target Upside569.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$36.13M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthSELLAS’s very low leverage and materially improved equity position provide durable financial flexibility, reducing interest burden and preserving options to fund R&D. This balance-sheet strength supports continued clinical activity and strategic choices over the next several months.
Improved LiquidityA cash stockpile (~$107M) plus ~$28.7M from recent warrant exercises materially extends runway for clinical programs. For a clinical-stage biotech, this durable liquidity reduces immediate financing pressure and supports program execution and regulatory activities over the medium term.
Governance & Incentive CapacityShareholder approvals for board continuity, auditor ratification and expanded equity incentive capacity strengthen governance and talent retention. This durable oversight and incentive flexibility aid management continuity and execution of multi-month clinical and strategic initiatives.
Bears Say
Persistent Cash BurnConsistently negative operating and free cash flow (TTM ≈ -$28.2M) represent structural cash burn. This ongoing deficit forces reliance on external capital to sustain development, increasing execution risk if financing conditions tighten and potentially delaying trials or programs.
No Commercial RevenueEffectively zero revenue across recent years and a TTM net loss (~$29.5M) mean SELLAS lacks a commercial cash-generating base. This structural absence of income extends dependence on financings, depresses returns on equity, and elevates long-term dilution and execution risk until commercialization.
Shareholder DilutionThe rise in shares outstanding (~196.6M) after warrant exercises signals continued reliance on equity financing. Persistent dilution can erode per-share economics, raise the effective cost of future capital, and reduce long-term upside for existing shareholders if commercial success is delayed.
SELLAS Life Sciences Group News
SLS FAQ
What was Sellas Life Sciences Group’s price range in the past 12 months?
Sellas Life Sciences Group lowest stock price was $1.39 and its highest was $15.88 in the past 12 months.
What is Sellas Life Sciences Group’s market cap?
Sellas Life Sciences Group’s market cap is $2.40B.
When is Sellas Life Sciences Group’s upcoming earnings report date?
Sellas Life Sciences Group’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were Sellas Life Sciences Group’s earnings last quarter?
Sellas Life Sciences Group released its earnings results on May 12, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.01.
Is Sellas Life Sciences Group overvalued?
According to Wall Street analysts Sellas Life Sciences Group’s price is currently Undervalued.
Does Sellas Life Sciences Group pay dividends?
Sellas Life Sciences Group does not currently pay dividends.
What is Sellas Life Sciences Group’s EPS estimate?
Sellas Life Sciences Group’s EPS estimate is -0.05.
How many shares outstanding does Sellas Life Sciences Group have?
Sellas Life Sciences Group has 186,032,580 shares outstanding.
What happened to Sellas Life Sciences Group’s price movement after its last earnings report?
Sellas Life Sciences Group reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went up 25.096%.
Which hedge fund is a major shareholder of Sellas Life Sciences Group?
Currently, no hedge funds are holding shares in SLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SELLAS Life Sciences Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.50 (569.10% Upside)
$27.50 (569.10% Upside)
Blogger Sentiment
Bullish
SLS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 88.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
597.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
226.63%
Trailing 12-Months
Company Description
Sellas Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
SLS Stock 12 Month Forecast
Average Price Target
$27.50
▲(569.10% Upside)
Technical Analysis
Galectin Therapeutics
―
Voyager Therapeutics
―
Tiziana Life Sciences
―
Diamedica Therapeutics
―
Black Diamond Therapeutics
―
Ownership Overview
1.80% Insiders
6.63% Mutual Funds
0.95% Other Institutional Investors
75.01% Public Companies and
Individual Investors